Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151…
Biotechnology
US, South San Francisco [HQ]
DNLI/Leadership and Strategy
Risk Factors
Annual
Not Available
No Risk Factor available yet. You can request "Risk Factors" through an email.
Quarter
Not Available